AREDIA
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Oct 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AREDIA (pamidronate disodium) is an intravenous bisphosphonate approved in 1991 for managing hypercalcemia of malignancy and osteolytic bone metastases in multiple myeloma and breast cancer. It works by inhibiting osteoclast-mediated bone resorption, reducing serum calcium levels and bone destruction in cancer patients.
LOE Approaching
Moderate competitive pressure (30/100) signals a mature, defensible market position with stable but not growing team requirements as LOE approaches.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked jobs and an LOE-approaching lifecycle, AREDIA offers limited career growth opportunities; roles are primarily focused on defending market share against generics and managing transition strategy. This is a mature, stable role suitable for leveraging established product expertise rather than launching new initiatives.
Brand ManagerField Sales Representative
Worked on AREDIA at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.